Need professional-grade analysis? Visit stockanalysis.com
$5.58M
N/A
N/A
N/A
XTL Biopharmaceuticals Ltd ADR (XTLB) trades on United States in USD. The company is classified in the Healthcare sector under the Pharmaceutical Preparations industry. The stock currently trades at $2.44, down 2.59% from the previous close.
Over the past year, XTLB has traded between a low of $0.58 and a high of $2.71. The stock has gained 81.8% over this period. It is currently 9.8% below its 52-week high.
XTL Biopharmaceuticals Ltd ADR has a market capitalization of $5.58M.
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel.
Side-by-side comparison against top Healthcare peers.